11.13
-0.2535(-2.23%)
Currency In USD
| Previous Close | 6.27 |
| Open | 11.04 |
| Day High | 11.4 |
| Day Low | 10.85 |
| 52-Week High | 11.41 |
| 52-Week Low | 2.87 |
| Volume | 83.43M |
| Average Volume | 4.81M |
| Market Cap | 1.01B |
| PE | -5.39 |
| EPS | -2.11 |
| Moving Average 50 Days | 4.97 |
| Moving Average 200 Days | 5.74 |
| Change | 5.11 |
If you invested $1000 in Verve Therapeutics, Inc. (VERV) since IPO date, it would be worth $356.52 as of June 18, 2025 at a share price of $11.38. Whereas If you bought $1000 worth of Verve Therapeutics, Inc. (VERV) shares 3 years ago, it would be worth $873.37 as of June 18, 2025 at a share price of $11.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Verve Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
BOSTON , May 28, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that management will participate in fireside chats during the following i
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
GlobeNewswire Inc.
Apr 14, 2025 11:00 AM GMT
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related ser
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
GlobeNewswire Inc.
Apr 11, 2025 11:00 AM GMT
BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track